ClinicaliQ Trial Snapshot
- A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis — Recruiting • Phase III • Rheumatology • NCT03773965.
- Baricitinib safety and effectiveness for children aged 1-17 with juvenile idiopathic arthritis.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU. Conditions: Juvenile Idiopathic Arthritis Interventions: Baricitinib Lead Sponsor: Eli Lilly and Company Planned Enrollment: 190 participants